OcuDyne is a clinical-stage medical device company developing a novel therapy to treat Age Related Macular Degeneration (AMD), the leading cause of irreversible vision loss in the elderly worldwide.
As a world leader in the evaluation of ocular perfusion and how it influences ocular health, OcuDyne’s mission is to develop therapies that improve blood flow to the eye. Impaired blood flow causes disease in organ systems all over the body, and the eye is no exception. Over the past few years, advances in intracranial and arterial imaging have shown that impared ocular perfusion is present in patients suffering from AMD. As a result, AMD is the first indication being pursued by OcuDyne.